Executive Team

Massive Bio's multidisciplinary team has in-depth business and healthcare experience consisting of oncologists, molecular diagnostic scientists, reimbursement experts, and data scientists.

Selin Kurnaz, PhD
Lead-founder and CEO

Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a decade specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Healthcare and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways. Massive Bio is an alumni of eLab and PhilipsHealthworks Precision Cancer Care start-up acceleration programs.

Dr. Arturo Loaiza-Bonilla, MD MSEd
Co-founder and Chief Medical Advisor

Dr. Arturo Loaiza-Bonilla is the current Vice Chairman of the Department of Medical Oncology at Cancer Treatment Centers of America (CTCA), Chief of Medical Oncology and Medical Director of Research at CTCA - Philadelphia. A dedicated practicing clinician, international speaker, and precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to optimize clinical workflows and trial design (adaptive trials, synthetic control arms, basket trials), and matching for oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient's overall status in treatment decision making, with special interest in Artificial Intelligence-based / machine and deep learning platforms.


Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, technology, wearables, medical education, block chain, organized medicine leadership and health policy, having been awarded the 'Top 40 Under 40' award by the Philadelphia Business Journal, Castle Connolly’s Top Doctor listing, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania. He has held several leadership positions in state and medical societies, including his tenure as executive board member of the Pennsylvania Society of Oncology and Hematology (ASCO State Affiliate), and his role as President of the Board of Directors of the Global Alliance for Patient Access.

Cagatay M. Culcuoglu
Cagatay M. Culcuoglu, MBA
Co-founder, Chief Operating Officer & Chief Technology Officer

Mr. Culcuoglu leads operational strategy, global business initiatives, product and technology development at Massive Bio. Mr. Culcuoglu has developed several products over the past 20 years, primarily for the financial, media and health industry. A serial entrepreneur, Mr. Culcuoglu co-founded startups, where he also led business and sales operations as well technology and product development. Mr. Culcuoglu took senior roles at Thomson Reuters, Mubasher, KPMG, Sabrient Systems, Anadolu Agency, Merrill Lynch and Smeal College. Mr. Culcuoglu is an active board member in multiple start-ups and an owner of a media company. In addition, Mr. Culcuoglu holds an MBA degree from Pennsylvania State University and MA degree from University of Maastricht.

Kristin Johnston
Kristin Johnston, RN
Chief Nursing Officer

Kristin Johnston is an Oncology Certified Registered Nurse, and is Massive Bio's Chief Nursing Officer. She has more than a decade of experience in helping cancer patients explore options and has personally guided thousands of patients through the clinical trial decision and enrollment process. Her role is to answer clinical questions and ensure patients have the support they need throughout their partnership with Massive Bio.

Jo Marie Victor
Jo Marie Victor
VP of Operations & HR

Jo Marie Victor, as VP of Operations at Massive Bio, supports the mission, growth, profitability, compliance, business development strategy, enterprise customer relationship management, and overall operations of Massive Bio. Jo Marie has extensive experience in the healthcare industry specifically in customer service management, call center leadership, Human Resources, and overall operations metrics, process and workflows.


As a Director of Customer Service within Operations at Independence Blue Cross, and USI Affinity, she gained in-depth operational knowledge, associate engagement, client interfacing, and extensive business development acumen. During that juncture, Jo Marie presented regularly throughout the various Chamber of Commerce’s in the five county PA. region on relative Healthcare topics. She is also an adjunct professor at Chestnut Hill College and an Alumni board member. She has volunteered for many organizations, but most significantly, she was an Executive Campaign team member for United Way. Jo Marie received her Bachelor of Science degree from Chestnut Hill College, and post-graduate work from Rosemont College.

Fiona Evans
Fiona Evans
Lead Patient Advocate

In her role as Lead Patient Advocate, Fiona works directly with our patients and families, guiding them through Massive Bio's innovative cancer care. Fiona is focused on providing patient and family teaching regarding the specific treatment options offered by Massive Bio. She will assist in identifying individual care needs and guide them through the process of finding the right treatment options for their specific case. Born and raised in the United Kingdom, Fiona came to the United States with her family. She has spent the past 14 years working in various positions within the healthcare field, including cardiology, colon and rectal, surgery, and general medicine. Caring for patients with acute needs in inpatient settings and subacute needs in outpatient settings, has enabled Fiona to evaluate medical concerns from a variety of perspectives.

Jason Freedman
Dr. Jason L. Freedman, MD MSCE
Chief Pediatric Advisor

Jason Freedman, MD, MSCE is a Board Certified Pediatric Oncologist who graduated with honors from Cornell University and received his medical degree Magna Cum Laude from Upstate Medical University in Syracuse, NY. Dr. Freedman completed his residency in Pediatrics at the Children’s Hospital of NY-Presbyterian (Columbia University) and served as Pediatric Chief Resident, thereafter. He completed fellowship training in Pediatric Hematology/Oncology at Children’s Hospital of Philadelphia (CHOP), during which time he earned a Master’s of Science in Clinical Epidemiology (MSCE) from the University of Pennsylvania.


Dr. Freedman has received numerous awards and honors including induction into the Alpha Omega Alpha medical honor society, and nominations into the President’s Circle of Excellence and Attending of the Year at the Children’s Hospital of NY-Presbyterian. During fellowship at The Children’s Hospital of Philadelphia, he was the recipient of the William Potash Fellow Teacher of the Year for his commitment to resident education and clinical excellence. As a faculty member at PENN/CHOP, he has earned a Distinguished Teaching Award and was selected for the early career faculty honor roll.

Dr. Freedman is an attending physician in Oncology at CHOP, where he also has administrative and teaching responsibilities. Dr. Freedman’s clinical focus is blood and marrow transplantation and hematologic malignancies. He has a particular interest in quality improvement and supportive care, and serves on several national committees. Dr. Freedman has authored several textbook chapters and peer-reviewed articles on the care of children with cancer and has contributed to the development of clinical guidelines to standardize management of symptoms associated with cancer therapy.

Josh Komins
Josh Komins
Associate Marketing Specialist

As the Associate Marketing Specialist, Josh delivers marketing materials to patients directly, and through Massive Bio’s social media pages. Josh also focuses on creating informative and resourceful materials for cancer patients throughout the Massive Bio website. The Customer Relationship Management Software (CRM) is also managed by Josh, by supporting the patient advocates and their ability to provide resources to our cancer patients. Since graduating from West Virginia University last year with a degree in Marketing, Josh has learned about the cancer industry and what it means to help cancer patients through working with Massive Bio. Josh has utilized and adapted what he has learned to improve Massive Bio’s ability to help cancer patients.

Eldar Gadirov
Application Developer

As an Application Developer for Massive Bio, Eldar designs and modernizes the technology products offered by Massive Bio. In the world of high technology, Eldar creates an intuitive interface for our patients. Behind the scenes, Eldar spearheads this complex logic so Massive Bio’s technology services exceed expectations. He focuses on simplification of our processes with the ultimate goal to expedite clinical trials for our customers. His motto is "Making the impossible possible".

Board Members and Commercial Advisors

Primo Beadling

VP of Operations at IPB

Simin Zhou

Managing Director of UL Ventures

Paul Tanico

President at Castlerock Asset Management

Rina Sirinoglu

General Partner at 500 Startups

Kojo Appenteng

Managing Director

Gyan Kapur

Managing Director at Bayes Ventures

Scientific Advisory Board

Massive Bio’s scientific advisory board provides subject matter expertise as it relates to the current treatment practices for cancer and how they may be evolving. Our board evaluates:

  Current cancer treatment decisions on the selection of chemotherapy, backbones/biologics, and the sequencing of therapies based on recent data from world scientific meetings (ASCO, ESMO, AACR, etc.).
  Patient selection and approach towards personalized treatment with respect to tumor profiling and biomarker assessment.
  Economic analyses of cancer and how real world data (RWD) studies looking at effectiveness and costs would factor into treatment paradigms.
  Economic analyses of cancer and how real world data (RWD) studies looking at effectiveness and costs would factor into treatment paradigms.
  The role of immunotherapy checkpoint inhibitors in cancer and other immune-oncology approaches in development.

Maurie Markman
Dr. Maurie Markman

Maurie is a nationally renowned oncologist and has more than 20 years of experience in cancer treatment and gynecologic research at some of the country's most recognized facilities, including MD Anderson Cancer Center, the Cleveland Clinic and Memorial Sloan-Kettering Cancer Center. In June 2011, he received the esteemed American Society of Clinical Oncology (ASCO) Statesman Award. Presented annually, the Statesman Award recognizes individual ASCO members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years. Dedicated to finding new and innovative ways to treat cancer, Dr. Markman has published more than 1400 articles, editorials, peer-reviewed manuscripts, book chapters, reviews, letters and abstracts.


He has also written or co-edited 10 books and served as an editorial board member on over 40 journals. He is currently Editor-in-Chief of numerous oncology journals, including Oncology Digest and Current Oncology Reports. He is also a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Dr. Markman is regularly listed as one of the “Best Doctors in America” by Best Doctors, Inc., one of “America’s Top Doctors” by Castle Connelly Medical Ltd., and one of “America’s Top Oncologists” by Consumer’s Research Council of America. In 1999 he was recognized as the Lee and Jerome Burkons Research Chair in Oncology by the Cleveland Clinic.

Stefan Glück
Dr. Stefan Glück

Stefan leads early stage development of solid tumors and immuno-oncology in one of the largest the pharmaceutical companies. Stefan was the Sylvester Professor at the Miller School of Medicine at the University of Miami in Florida. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute. Before his move to Miami, Dr. Glück was Director, Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, and a Professor in the departments of oncology, medicine, pharmacology and therapeutics at the University of Calgary in Alberta, Canada, and Deputy Head, Department of Oncology at the University of Calgary.


Dr. Glück was presented the America’s Top Oncologists award from Consumers’ Research Council of America. He was also recognized as one of the Best Doctors in America from 2006 through 2012. He has authored or co-authored more than 200 articles. In addition, Dr Glück has written or co-written a number of book chapters and numerous journal abstracts, and he has presented more than 350 papers at national and international meetings.

Edgardo Santos
Dr. Edgardo Santos

Edgardo practices at the Center for Hematology-Oncology (CHO) and is an Associate Professor of Clinical Biomedical Sciences at Florida Atlantic University, and Vice Chairman of the FLASCO Membership Committee. He earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos completed his internship and residency training in Internal Medicine at Jackson Memorial Medical Center, University of Miami School of Medicine, Miami, Florida. Then, he went on to complete his fellowship in Hematology/Oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida.


Dr. Santos has authored or co-authored several manuscripts in peer-reviewed journals and also serves as reviewer for several scientific publications. Dr. Santos is a member of the Editorial Board of Expert Review series, Recent Patents on Biomarkers, and Clinical Practice. He has lectured mostly on topics related to lung and head and neck cancers as well as lymphoproliferative disorders and multiple myeloma. Dr. Santos’ main interests are the conduction and development of early phases of clinical trials. Furthermore, he has recently been selected by The International Association of HealthCare Professionals (IAHCP) to be published in the premier publication of The Leading Physicians of the World.